NHS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®)

Offer reference number: CM/PHR/20/5600
CM/PHR/20/5600/01 – NHS Framework for the North of England, Branded Medicines -Tranche B – 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
CM/PHR/20/5600/02 – NHS Framework for the North of England, Branded Medicines – Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.
CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England – Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.
CM/PHR/20/5600/04 – NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London – Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/20/5600/05 – NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East – Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.